Compare Cassava Sciences Inc (FLNA) vs HCA Health Inc (HCA) Price & Performance

Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.

The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.

HCA Healthcare (HCA) is trading at $363.60, down 6.95% amid lowered 2026 guidance. The stock shows bearish technical signals but maintains strong fundamentals with consistent revenue growth to $75.6 billion in 2025 and earnings beats in recent quarters. Analyst consensus remains bullish with a $469.40 price target despite recent negative sentiment from payer mix challenges.

The outlook presents a value opportunity given attractive valuation multiples (P/E 13.05, EV/EBITDA 8.48) and dividend yield, though risks include rising uninsured patients and margin compression. Long-term growth drivers include capacity expansion and specialty care investments, but near-term volatility may persist until Q2 earnings clarity.